Following the agreement, it has reached with Université Laval and the CERVO Brain Research Centre of the CIUSSS de la Capitale Nationale, the venture capital fund will finance the development of a project on the SRSF3 target in the laboratory of Dr Jasna Kriz.
AmorChem is based Montreal, and focused on creating promising life science companies from technologies originating primarily from Quebec-based universities and research centres.
Launched in 2011, the AmorChem I Fund model combines access to financial resources with a virtual incubator structure that enables the rapid development and commercialisation of its technologies.
The first fund (41.2MUSD) has built a portfolio of 24 technologies and successfully transacted two pharma exits as well as spun-out six companies. The attractiveness of this seed fund model and the role it plays in the investment ecosystem were highlighted in September 2017 with the launch of the AmorChem II Fund, which now totals USD 45.7m.
UCB reports positive Phase 3 results for fenfluramine in CDKL5 deficiency disorder
WuXi AppTec's Nantong site receives 2025 Architizer A+Award
MGI partners with Negedia to enhance genomic sequencing in Italy
Speranza Therapeutics partners with Sunshine Labs for harm reduction solutions
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Aptamer Group signs development and licensing deal with global life sciences partner
Scancell expands Phase 2 SCOPE trial with new intradermal dosing arm for iSCIB1+
Telix Pharmaceuticals delivers first commercial doses from Belgian manufacturing hub
CivicaScript introduces low-cost multiple sclerosis treatment
Innovent presents mazdutide Phase 3 clinical study results at ADA 85th Scientific Sessions
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress